Published in Biochem Soc Trans on August 01, 2007
Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol (2009) 2.99
Antimicrobial peptides. Pharmaceuticals (Basel) (2013) 1.37
Cell penetrating peptides: overview and applications to the delivery of oligonucleotides. Cell Mol Life Sci (2009) 1.31
Inhibition of transmitter release and attenuation of anti-retroviral-associated and tibial nerve injury-related painful peripheral neuropathy by novel synthetic Ca2+ channel peptides. J Biol Chem (2012) 0.94
Cell penetrating peptides in the delivery of biopharmaceuticals. Biomolecules (2012) 0.88
Endocytosis and membrane potential are required for HeLa cell uptake of R.I.-CKTat9, a retro-inverso Tat cell penetrating peptide. Mol Pharm (2009) 0.88
Cell permeable cocaine esterases constructed by chemical conjugation and genetic recombination. Mol Pharm (2012) 0.81
dNP2 is a blood-brain barrier-permeable peptide enabling ctCTLA-4 protein delivery to ameliorate experimental autoimmune encephalomyelitis. Nat Commun (2015) 0.81
Building Cell Selectivity into CPP-Mediated Strategies. Pharmaceuticals (Basel) (2010) 0.78
XG-102 administered to healthy male volunteers as a single intravenous infusion: a randomized, double-blind, placebo-controlled, dose-escalating study. Pharmacol Res Perspect (2014) 0.75
Targeting the Tumour: Cell Penetrating Peptides for Molecular Imaging and Radiotherapy. Pharmaceuticals (Basel) (2010) 0.75
Casein kinase iepsilon in the wnt pathway: regulation of beta-catenin function. Proc Natl Acad Sci U S A (1999) 2.25
Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin Cł. Cancer Res (1992) 1.38
Sequence-specific DNA binding by a two zinc-finger peptide from the Drosophila melanogaster Tramtrack protein. J Mol Biol (1992) 1.37
Intravascular bullet localization by sonography. AJR Am J Roentgenol (1996) 1.12
Loss of tramtrack gene activity results in ectopic R7 cell formation, even in a sina mutant background. Proc Natl Acad Sci U S A (1996) 1.10
Mosaic analysis using FLP recombinase. Methods Cell Biol (1994) 1.07
Comparison of clinical outcome of periapical surgery in endodontic and oral surgery units of a teaching dental hospital: a retrospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2001) 1.00
Preclinical antitumor activity of an alpha-picoline derivative, penclomedine (NSC 338720), on human and murine tumors. Cancer Res (1989) 0.99
Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo. Cancer Res (1994) 0.99
Assessment of morbidity of semitendinosus and gracilis tendon harvest for ACL reconstruction. Am J Knee Surg (1997) 0.97
Hematology and clinical chemistry reference values for C57BL/6 X DBA/2 F1 mice. Cancer Res (1978) 0.95
Response of human tumor xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere). Invest New Drugs (1995) 0.94
Antitumor activity of ethyl 5-amino-1,2-dihydro-2-methyl-3-phenyl-pyrido [3,4-b]pyrazin-7-ylcarbamate, 2-hydroxyethanesulfonate, hydrate (NSC 370147) against selected tumor systems in culture and in mice. Cancer Res (1990) 0.94
Usefulness of turbo spin-echo MR imaging in the evaluation of meniscal tears: comparison with a conventional spin-echo sequence. AJR Am J Roentgenol (1996) 0.93
Partial inhibition of multidrug resistance by safingol is independent of modulation of P-glycoprotein substrate activities and correlated with inhibition of protein kinase C. J Biol Chem (1995) 0.93
Toxicity of the protein kinase C inhibitor safingol administered alone and in combination with chemotherapeutic agents. Fundam Appl Toxicol (1995) 0.92
Upper gastrointestinal tract and abdomen: water as an orally administered contrast agent for helical CT. Radiology (1996) 0.88
Preclinical antitumor activity of batracylin (NSC 320846). Invest New Drugs (1988) 0.88
Practical spontaneous metastasis model for in vivo therapeutic studies using a human melanoma. Cancer Res (1991) 0.86
The interaction of bride of sevenless with sevenless is conserved between Drosophila virilis and Drosophila melanogaster. Proc Natl Acad Sci U S A (1993) 0.85
Correlation of metal toxicity with in vitro calmodulin inhibition. Biochem Biophys Res Commun (1983) 0.84
Preclinical antitumor activity and pharmacological properties of deoxyspergualin. Cancer Res (1987) 0.83
Massive tricuspid regurgitation identified on renal flow scintigraphy. Clin Nucl Med (1991) 0.82
Qualitative and quantitative toxicity of single and sequential sublethal doses of 5-fluorouracil in BDF mice. Cancer Treat Rep (1978) 0.81
Effect of nitrous oxide on intracranial pressure after cranial-dural closure in patients undergoing craniotomy. Anesthesiology (1992) 0.79
Evaluation of trans-tetrachloro-1,2-diaminocyclohexane platinum (IV) in murine leukemia L1210 resistant and sensitive to cis-diamminedichloroplatinum (II). Cancer Chemother Pharmacol (1987) 0.79
Cardiac-gated MR angiography of the entire lower extremity: a prospective comparison with conventional angiography. AJR Am J Roentgenol (1996) 0.78
Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia. Cancer Chemother Pharmacol (1991) 0.78
Antitumor activity and cross-resistance of carmethizole hydrochloride in preclinical models in mice. Cancer Chemother Pharmacol (1992) 0.78
Comparative physiological disposition of melatonin and its benzo(b)thiophene analog in the rat. Life Sci (1974) 0.78
Comparative subchronic toxicity of all-trans- and 13-cis- retinoic acid in Sprague--Dawley rats. Toxicol Appl Pharmacol (1979) 0.78
Antitumor activity of 2-chloroethyl (methylsulfonyl)methanesulfonate (clomesone, NSC 33847) against selected tumor systems in mice. Cancer Res (1989) 0.77
An investigation of the mouse as a model for vincristine toxicity. Cancer Chemother Pharmacol (1983) 0.76
Use of intra-articular morphine for postoperative analgesia following TMJ arthroscopy. Br J Oral Maxillofac Surg (1999) 0.75
Comment on McQuay et al., PAIN, 68 (1996) 217-227. Pain (1998) 0.75
Growth of human tumor cells in athymic mice. J Natl Cancer Inst (1991) 0.75
Orthodontics as a risk factor for temporomandibular disorders (TMD). II. Am J Orthod Dentofacial Orthop (1992) 0.75
Effects of prochlorperazine on experimental nephrotoxicity. Cancer Chemother Pharmacol (1982) 0.75
Hematologic and histopathologic evaluation of N-(phosphonacetyl)-L-aspartate (PALA) in mice. Cancer Chemother Pharmacol (1979) 0.75
Tumor models in drug development. Cancer Metastasis Rev (1991) 0.75
Polyamide thin-layer chromatographic separation of DOPA metabolites and related compounds. J Chromatogr (1973) 0.75
Antitumor drug cross-resistance in vivo in a murine P388 leukemia resistant to ethyl 5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7 - ylcarbamate 2-hydroxyethanesulfonate hydrate (NSC 370,147) 370147. Cancer Chemother Pharmacol (1992) 0.75
Cross-resistance of drug-resistant murine P388 leukemias to taxol in vivo. Cancer Chemother Pharmacol (1992) 0.75
Optically active dithiothreitol. Toxicity and radiation-protective activity. J Med Chem (1972) 0.75
Fluorometric method for the determination of lapachol in serum. Anal Chem (1969) 0.75
Modulation of cytosine arabinoside toxicity by 3-deazauridine in a murine leukemia model. Leuk Res (1991) 0.75
Evaluation of the antitumor activity of recombinant human gamma-interferon employing human melanoma xenografts in athymic nude mice. Cancer Res (1987) 0.75
Physiological disposition of atropine in the rat. Pharmacol Biochem Behav (1975) 0.75
Excision assay for initial evaluation of antitumor drug activity in mice bearing human tumor xenografts. J Natl Cancer Inst (1992) 0.75
Inhibitory effects of calmodulin antagonists on urinary enzyme excretion in rats after nephrotoxic doses of mercuric chloride. Bull Environ Contam Toxicol (1985) 0.75
Arabinosyl-5-azacytosine: a novel nucleoside entering clinical trials. Invest New Drugs (1987) 0.75
Binding of the epoxide cryptophycin analog, LY355703 to albumin and its effect on in vitro antiproliferative activity. Oncol Rep (1998) 0.75
Evidence for toxicologic activity of ftorafur independent of conversion to 5-fluorouracil. Cancer Treat Rep (1979) 0.75
Inability of rat brain homogenate to oxidize amphetamine. Biochem Pharmacol (1974) 0.75
Antitumor drug toxicity in tumor-free and tumor-bearing mice. Cancer Chemother Pharmacol (1980) 0.75
Metabolism of 3-(2-dimethylaminoethyl)benzo(b)thiophene in vitro and in vivo in the rat. Drug Metab Dispos (1974) 0.75
Mass spectra of biologically active indole, 1-methylindole, and benzo(b)thiopene derivatives. Res Commun Chem Pathol Pharmacol (1974) 0.75
Qualitative and quantitative toxicity of sublethal doses of methyl-CCNU in BDF1 mice. Cancer Treat Rep (1977) 0.75
Effect of nitrosoureas on calmodulin activity in vitro and in mouse intestine in vivo. Cancer Chemother Pharmacol (1985) 0.75
Letter: Etiology of heroin-associated nephropathy. N Engl J Med (1974) 0.75
MMPI study of identical twins: cancer patients and bone marrow donors. Psychol Rep (1987) 0.75
Life change and onset of cancer in identical twins. J Psychosom Res (1984) 0.75
Body dysmorphic disorder involving the facial region: a report of 6 cases. J Oral Maxillofac Surg (2000) 0.75
Activated carbon fibers for hemoperfusion. Trans Am Soc Artif Intern Organs (1974) 0.75
Effect of aspirin administration on retinoic acid toxicity in mice. Nature (1977) 0.75
Toxicologic evaluation of cis-diamminedichloroplatinum II in B6D2F1 mice. Fundam Appl Toxicol (1983) 0.75
Therapeutic synergism of tiazofurin and selected antitumor drugs against sensitive and resistant P388 leukemia in mice. Cancer Res (1986) 0.75
Tween 80 increases plasma adriamycin concentrations in mice by an apparent reduction of plasma volume. Eur J Cancer (1981) 0.75
Effect of nonsteroidal anti-inflammatory drugs on sublethal retinoic acid toxicity in Swiss mice. Biochem Pharmacol (1981) 0.75